Alnylam: Bulls and Bears Clash After Revenue Cut
Alnylam's recent reduced revenue guidance sent investors into a panic, but analysts remain optimistic about the biotech's future.
Alnylam's share price peaked one year ago, reaching nearly $500 per share, fueled by the success of its transthyretin-mediated amyloidosis (ATTR) franchise. However, the stock has since plummeted to around $250 following a significant revenue guidance cut in July.
The Guidance Cut:
Alnylam's management lowered its full-year revenue guidance, citing shortfalls in second-quarter sales of its lead product, Amvuttra. This raised concerns among investors about the product's market potential, especially against rival small-molecule treatments.
Analyst Reactions:
-
Stifel: The revenue cut may create a temporary credibility issue and cast doubt on Amvuttra's peak sales potential.
-
Guggenheim Securities: The guidance revision suggests a smaller-than-expected commercial opportunity, mispricing, or a shift in preference towards TTR stabilizers.
Despite these concerns, some analysts remain bullish. TD Cowen assigned a $482 price target even after the guidance cut, and BMO Capital Markets, with a $318 price target, sided with the bulls on several key debates regarding Alnylam's prospects.
Key Debates:
-
ATTR Market Size: Alnylam bulls believe the ATTR market is substantial, while bears argue it's smaller than initially thought.
-
Nucresiran's Value: Bulls see potential in Alnylam's next-generation RNAi candidate, nucresiran, while bears question its value.
-
Gene Silencing's Future: Analysts disagree on whether gene silencing will become a prominent drug modality.
BMO analysts, optimistic about Alnylam's future, attribute the guidance cut to exhausted patient populations for Amvuttra, adjusting the sales ramp's trajectory rather than the overall opportunity.